文献速递系统性红斑狼疮

皮下注射阿尼鲁单抗在系统性红斑狼疮患者中的药代动力学、药效学与安全性:一项2期随机双盲安慰剂对照研究

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
PubMed 文献 · Lancet Rheumatol · 2020-11-20

这项多中心2期研究纳入36例伴有活动性皮肤病变和高I型干扰素基因表达特征的SLE患者,随机接受皮下阿尼鲁单抗150 mg、300 mg或安慰剂。第12周时阿尼鲁单抗呈非线性药代动力学,暴露量超过剂量比例增加,并剂量依赖性地中和I型干扰素基因表达特征;安全性特征与既往静脉制剂研究一致。

要点

  • 皮下阿尼鲁单抗在SLE患者中呈非线性药代动力学,暴露量超过剂量比例增加。
  • 第12周时阿尼鲁单抗剂量依赖性地中和I型干扰素基因表达特征。
  • 安全性特征与既往静脉阿尼鲁单抗研究一致,支持皮下剂型继续开发。

核心结论

  • 皮下注射阿尼鲁单抗在SLE伴中重度皮肤表现患者中呈非线性药代动力学且暴露量超过剂量比例增加,并剂量依赖性地中和I型干扰素基因表达特征。
  • 其安全性特征与既往静脉阿尼鲁单抗研究一致,支持皮下剂型作为SLE治疗的继续开发。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2期研究,在匈牙利、韩国、波兰和美国的12家医院及门诊开展。
  • 纳入18-70岁、SLE伴高I型干扰素基因表达特征且CLASI活动度评分至少10的患者。
  • 36例患者按3:1:3:1随机接受皮下阿尼鲁单抗150 mg、300 mg或对应安慰剂,联合稳定标准治疗。
  • 主要药代动力学终点为首剂后最大浓度及后续给药前谷浓度,主要药效学终点为第12周I型干扰素药效学特征中和。

主要发现

  • 中和率达75%及以上的患者比例:150 mg组8/12(67%),300 mg组10/13(77%),安慰剂组1/9(11%)。
  • 至少1例不良事件:阿尼鲁单抗组27例中23例(85%),安慰剂组9例中7例(78%),多为轻至中度。
  • 严重不良事件:阿尼鲁单抗组27例中6例(22%)(150 mg组4例,300 mg组2例),安慰剂组无报告;带状疱疹感染阿尼鲁单抗组3/27(11%),安慰剂组1/9(11%)。

关键数值与推荐

  • 入组要求CLASI活动度评分至少10且高I型干扰素基因表达特征。
  • 第12周后开始逐渐减量口服糖皮质激素。
  • 药效学中和评估基于21基因检测。

临床怎么用

  • 皮下阿尼鲁单抗每2周给药在SLE伴中重度皮肤病变患者中可剂量依赖性地中和I型干扰素基因表达特征。
  • 安全性特征与静脉制剂既往研究一致,支持皮下剂型继续开发。

局限性

  • 本研究为2期小样本研究,36例患者随机分组。
  • 研究双盲仅针对干预措施而非剂量,直至第12周。
  • 药效学分析排除了150 mg组2例患者(n=34)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 300 mg of intravenous anifrolumab every 4 weeks added to standard-of-care treatment for patients with systemic lupus erythematosus (SLE) reduced disease activity and glucocorticoid requirement in a previous phase 3 trial. Because patients might find subcutaneous administration more convenient than intravenous delivery, we aimed to evaluate the pharmacokinetics, pharmacodynamics, safety, and efficacy of subcutaneous anifrolumab in patients with SLE, active skin disease, and a high type I interferon gene signature. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 2 study was done at 12 hospitals and outpatient clinics in Hungary, South Korea, Poland, and the USA. Eligible patients were aged 18-70 years, and had SLE with high type I interferon gene signature and an activity score on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) of at least 10. Enrolled participants were randomly assigned (3:1:3:1) by use of a voice-web response system to receive either 150 mg of subcutaneous anifrolumab or corresponding placebo, or 300 mg of subcutaneous anifrolumab or corresponding placebo in addition to stable standard-of-care treatment. The study was double-blinded with respect to intervention but not dose, until 12 weeks. Doses of oral glucocorticoids were tapered after week 12. The primary pharmacokinetic endpoint was the serum concentration of anifrolumab based on the maximum concentration after the first dose and the minimum (trough) concentration before subsequent doses and was measured in all patients who received anifrolumab and had at least one quantifiable serum pharmacokinetics observation following the first dose. The primary pharmacodynamic endpoint was neutralisation of the type I interferon pharmacodynamic signature at week 12 and was assessed in all patients with a high type I interferon pharmacodynamics signature at baseline based on a 21-gene test. Safety was evaluated in the full analysis set, which included all patients who received at least one dose of anifrolumab. This trial is completed and is registered at ClinicalTrials.gov, NCT02962960. FINDINGS: Between March 14, 2017, and Oct 26, 2017, 36 patients were randomly assigned to receive 150 mg of anifrolumab (n=14), 300 mg of anifrolumab (n=13), or placebo (n=9). Two patients in the anifrolumab 150 mg group were excluded from the pharmacodynamic analysis set (n=34). Ten (71%) of 14 patients in the anifrolumab 150 mg group, ten (77%) of 13 patients in the anifrolumab 300 mg group, and nine (100%) of the nine patients in the placebo group completed 52 weeks of treatment. At week 12, pre-dose mean trough serum concentrations of anifrolumab were more than dose proportional between the anifrolumab 150 mg group (19·82 μg/mL [SD 15·01]) and the anifrolumab 300 mg group (60·28 μg/mL [43·66]), and the pharmacokinetics were non-linear. At week 12, the median percentage neutralisation of the type I interferon gene signature was higher with 150 mg (88·0% [median absolute deviation 7·4]) and 300 mg (90·7% [3·3]) of anifrolumab than with placebo (18·5% [8·1]), and more patients in the anifrolumab 150 mg group and the anifrolumab 300 mg group than in the placebo group had neutralisation of 75% or more (eight [67%] of 12 vs ten [77%] of 13 vs one [11%] of nine). At least one adverse event was reported by 23 (85%) of 27 patients in the anifrolumab groups and by seven (78%) of nine patients in the placebo group; most adverse events were of mild-to-moderate severity. Serious adverse events were reported in six (22%) of 27 patients in the anifrolumab groups (four patients in the 150 mg group and two in the 300 mg group). No serious adverse events were reported in the placebo group. Herpes zoster infection was reported by three (11%) of 27 patients in the anifrolumab groups and by one (11%) of nine patients in the placebo group. There were no treatment-related deaths. INTERPRETATION: Anifrolumab, administered subcutaneously every 2 weeks to patients with SLE and moderate-to-severe skin manifestations, had non-linear pharmacokinetics that were more than dose proportional, and neutralised the type I interferon gene signature in a dose-dependent manner. The safety profile was consistent with previous studies of intravenous anifrolumab, supporting the continued development of anifrolumab as a subcutaneously administered therapy for patients with SLE. FUNDING: AstraZeneca.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bruce IN, Nami A, Schwetje E, et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol. 2020. PMID: 38279367. doi:10.1016/S2665-9913(20)30342-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。